Vertex Pharmaceuticals (VRTX) Recently Broke Out Above the 20-Day Moving AverageZacks Investment Research • 12/02/21
Vertex Announces Positive Results From Phase 2 Study of VX-147 in APOL1-Mediated Focal Segmental GlomerulosclerosisBusiness Wire • 12/01/21
Vertex Announces Reimbursement Agreement in Spain for KAFTRIO® (ivacaftor/tezacaftor/elexacaftor) in Combination With Ivacaftor to Treat People With Cystic Fibrosis 12 Years and Older With At Least One F508del Mutation in the CFTR GeneBusiness Wire • 11/19/21
Vertex Receives CHMP Positive Opinion for KAFTRIO® (ivacaftor/tezacaftor/elexacaftor) in Combination With Ivacaftor in Children With Cystic Fibrosis Ages 6 Through 11Business Wire • 11/12/21
Wall Street Analysts Think Vertex (VRTX) Could Surge 36%: Read This Before Placing a BetZacks Investment Research • 11/08/21
Can Vertex Make Billions With a New Game-Changing Treatment? The Answer May Be Just AheadThe Motley Fool • 11/05/21
Vertex Pharmaceuticals Incorporated (VRTX) CEO Reshma Kewalramani on Q3 2021 Results - Earnings Call TranscriptSeeking Alpha • 11/03/21
Vertex Pharmaceuticals (VRTX) Tops Q3 Earnings and Revenue EstimatesZacks Investment Research • 11/02/21